RedHill Biopharma Announces Date of 2012 Financial Results and Corporate Update Conference Call

RedHill Biopharma Announces Date of 2012 Financial Results and Corporate
Update Conference Call

TEL-AVIV, Israel, Feb. 14, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd.
(Nasdaq:RDHL) (TASE:RDHL), an Israeli biopharmaceutical company focusing
primarily on development and acquisition of late clinical-stage,
patent-protected, new formulations and combinations of existing drugs,
announced that it plans to release its FY 2012 results on Tuesday, February
19th, 2013.

The Company will host a conference call and an audio webcast at 09:00am EST on
Wednesday, February 20th, 2013.

Date: February 20, 2013

Time: 9:00 AM ET

Listen via Internet:

Schedule this webcast into MS-Outlook calendar (click open when prompted):

Toll-free: 1 866 966 9439

International: 1 631 510 7498

Access code: # 11015754

About RedHill Biopharma Ltd.:

RedHill Biopharma is an emerging Israeli biopharmaceutical company focused
primarily on the development of late clinical-stage, patent protected, new
formulations and combinations of existing drugs. The Company's current product
pipeline includes a once-daily formulation of a leading congestive heart
failure and high blood pressure drug, a once-daily formulation of a leading
chemotherapy and radiotherapy-induced nausea and vomiting prevention drug, an
oral thin film formulation of a leading drug for the treatment of acute
migraine, a combination therapy for the treatment of Crohn's disease as well
as Multiple Sclerosis (MS) disease, a combination therapy for the treatment of
Helicobacter pylori bacteria causing ulcers, and an encapsulated formulation
for bowel preparation ahead of certain gastro procedures. For more information
please visit:

Statements in this Press Release that are not historical facts, including the
regulatory status of the programs and the expected timing and description of
the clinical trials, are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on the Company's current understanding of the regulatory
status and expectations of future events and are subject to significant
regulatory and development risks and uncertainties that could cause actual
results and development and regulatory progress to differ materially from
those expressed or implied by such statements, including (i) the initiation,
timing, progress and results of the Company's preclinical studies, clinical
trials, and other therapeutic candidate development efforts; (ii) the
Company's ability to advance its therapeutic candidates into clinical trials
or to successfully complete its preclinical studies or clinical trials; (iii)
the extent and number of additional studies that the Company may be required
to conduct and the Company's receipt of regulatory approvals for its
therapeutic candidates, and the timing of other regulatory filings and
approvals; (iv) the clinical development, commercialization, and market
acceptance of the Company's therapeutic candidates; (v) the Company's ability
to establish and maintain corporate collaborations; (vi) the interpretation of
the properties and characteristics of the Company's therapeutic candidates and
of the results obtained with its therapeutic candidates in preclinical studies
or clinical trials; (vii) the implementation of the Company's business model,
strategic plans for its business and therapeutic candidates; (viii) the scope
of protection the Company is able to establish and maintain for intellectual
property rights covering its therapeutic candidates and its ability to operate
its business without infringing the intellectual property rights of others;
(ix) estimates of the Company's expenses, future revenues capital requirements
and the Company's needs for additional financing; (x) competitive companies,
technologies and the Company's industry; and (xi) statements as to the impact
of the political and security situation in Israel on the Company's business.
More detailed information about the Company and the risk factors that may
affect the realization of forward-looking statements is set forth in the
Company's filings with the Securities and Exchange Commission (SEC), including
the Company's Registration Statement on From 20-F filed with the SEC on
December 26, 2012, and its Reports on Form 6-K. Investors and security holders
are urged to read these documents free of charge on the SEC's web site at All forward-looking statements included in this Press
Release are made only as of the date of this Press Release. We assume no
obligation to update any written or oral forward-looking statement made by us
or on our behalf as a result of new information, future events or other

CONTACT: RedHill Biopharma Ltd.
         Adi Frish (Senior VP Business Development and Licensing )

         Investor Relations:
         The Trout Group
         Lauren Glaser (Vice President )
Press spacebar to pause and continue. Press esc to stop.